ABVC BioPharma Receives $450,000 in Q3 Licensing Payments from OncoX Partnership
ABVC BioPharma's receipt of $450,000 in licensing payments from OncoX BioPharma highlights the financial strength of their oncology partnership and positions the company to capitalize on the growing $469 billion cancer therapeutics market.
ABVC BioPharma has received $450,000 in licensing payments from partner OncoX BioPharma during the third quarter of 2025, including $350,000 received in August. These payments demonstrate the ongoing financial benefits of the companies' strategic alliance focused on developing botanical-derived oncology treatments.
Under the licensing agreements, ABVC is entitled to $2.5 million in cash payments and 5 million OncoX shares, plus future royalties based on net sales. To date, the company has received $650,000 in cash payments, with $1.85 million remaining receivable and the equity consideration secured. The partnership covers four major oncology indications that have received FDA IND approvals: triple negative breast cancer, non-small cell lung cancer, myelodysplastic syndromes, and pancreatic cancer.
The collaboration positions both companies to benefit from the rapidly expanding global cancer therapeutics market. According to industry research from Precedence Research, the market was valued at approximately $194.67 billion in 2024 and is projected to reach $469.38 billion by 2034, representing a compound annual growth rate of 9.2%.
Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized the significance of the payments, stating that they demonstrate the execution strength of the collaboration. He noted that at the group level, including subsidiary BioLite, ABVC collectively is entitled to $3.75 million in total cash consideration and 7.5 million OncoX shares, highlighting both immediate liquidity and long-term equity value.
The OncoX CEO added that the partnership reflects their vision of combining innovation with strategic collaborations to create long-term value. The licensing agreement, together with OncoX's acquisition of the Lycogen platform for $4.06 million, demonstrates the company's commitment to expanding its oncology portfolio and preparing for global market opportunities.
This licensing partnership strengthens ABVC's strategic positioning in oncology by combining immediate and potential cash inflows, equity holdings, and future royalty streams. The framework has a consolidated value exceeding $41 million excluding royalties, cementing ABVC's leadership in advancing botanical-derived oncology therapeutics toward global commercialization.